ABSI - שווי פעילות לרווח לפני ריבית, מסים ופחת Absci Corporation

This price action chart on the GURU.Markets platform illustrates the performance of Absci (ABSI), which integrates generative AI and robotics to accelerate antibody design, with an EV/EBITDA metric of 0.00. The business relies on leasing external cloud computing and outsourcing logistics to focus on drug discovery. Despite massive R&D expenditures and a lack of profitability, alliances with the largest pharmaceutical behemoths mitigate the risks.

The integration of AI into antibody design at Absci makes the EV/EBITDA valuation trend a key tool for analyzing the value of this high-tech asset. This multiple compares the total enterprise value, including debt, with its operating profit before depreciation and amortization. The calculation determines the real price of the business, stripped of tax and credit effects. For an investor, an increase in this metric signals inflated market expectations regarding future earnings.